1
|
Wang Y, Minami Y, Ode KL, Ueda HR. The role of calcium and CaMKII in sleep. Front Syst Neurosci 2022; 16:1059421. [PMID: 36618010 PMCID: PMC9815122 DOI: 10.3389/fnsys.2022.1059421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Accepted: 12/05/2022] [Indexed: 12/24/2022] Open
Abstract
Sleep is an evolutionarily conserved phenotype shared by most of the animals on the planet. Prolonged wakefulness will result in increased sleep need or sleep pressure. However, its mechanisms remain elusive. Recent findings indicate that Ca2+ signaling, known to control diverse physiological functions, also regulates sleep. This review intends to summarize research advances in Ca2+ and Ca2+/calmodulin-dependent protein kinase II (CaMKII) in sleep regulation. Significant changes in sleep phenotype have been observed through calcium-related channels, receptors, and pumps. Mathematical modeling for neuronal firing patterns during NREM sleep suggests that these molecules compose a Ca2+-dependent hyperpolarization mechanism. The intracellular Ca2+ may then trigger sleep induction and maintenance through the activation of CaMKII, one of the sleep-promoting kinases. CaMKII and its multisite phosphorylation status may provide a link between transient calcium dynamics typically observed in neurons and sleep-wake dynamics observed on the long-time scale.
Collapse
Affiliation(s)
- Yuyang Wang
- Department of Systems Pharmacology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Yoichi Minami
- Department of Systems Pharmacology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Koji L. Ode
- Department of Systems Pharmacology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Hiroki R. Ueda
- Department of Systems Pharmacology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan,Laboratory for Synthetic Biology, RIKEN Center for Biosystems Dynamics Research, Suita, Japan,*Correspondence: Hiroki R. Ueda,
| |
Collapse
|
2
|
Kong W, Liu Y, Huang C, Zhou L, Gao J, Turner NJ, Jiang Y. Direct Asymmetric Reductive Amination of Alkyl (Hetero)Aryl Ketones by an Engineered Amine Dehydrogenase. Angew Chem Int Ed Engl 2022; 61:e202202264. [DOI: 10.1002/anie.202202264] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Indexed: 02/03/2023]
Affiliation(s)
- Weixi Kong
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Yunting Liu
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Chen Huang
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Liya Zhou
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Jing Gao
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Nicholas J. Turner
- Department of Chemistry University of Manchester Manchester Institute of Biotechnology 131 Princess Street Manchester M1 7DN UK
| | - Yanjun Jiang
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| |
Collapse
|
3
|
Kong W, Liu Y, Huang C, Zhou L, Gao J, Turner NJ, Jiang Y. Direct Asymmetric Reductive Amination of Alkyl (Hetero)Aryl Ketones by an Engineered Amine Dehydrogenase. Angew Chem Int Ed Engl 2022. [DOI: 10.1002/ange.202202264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Weixi Kong
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Yunting Liu
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Chen Huang
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Liya Zhou
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Jing Gao
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| | - Nicholas J. Turner
- Department of Chemistry University of Manchester Manchester Institute of Biotechnology 131 Princess Street Manchester M1 7DN UK
| | - Yanjun Jiang
- School of Chemical Engineering and Technology Hebei University of Technology No. 8 Guangrong Road, Hongqiao District Tianjin 300130 China
| |
Collapse
|
4
|
Zhong YL, Moore JC, Shevlin M, Shultz CS, Kosjek B, Chen Y, Janey JM, Tan L. Scalable Asymmetric Synthesis of MK-8998, a T-Type Calcium Channel Antagonist. J Org Chem 2021; 87:2120-2128. [PMID: 34582192 DOI: 10.1021/acs.joc.1c01795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Two scalable and efficient synthetic routes for the synthesis of a T-type calcium channel antagonist MK-8998 were developed from a simple pyridine building block. The key step to set the stereochemistry relied on either chiral rhodium catalyst-mediated asymmetric hydrogenation of an enamide or transamination of an arylketone that provided the corresponding product in high enantioselectivity and high yield.
Collapse
Affiliation(s)
- Yong-Li Zhong
- Process Research and Development, Merck & Company, Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - Jeffrey C Moore
- Process Research and Development, Merck & Company, Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - Michael Shevlin
- Process Research and Development, Merck & Company, Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - C Scott Shultz
- Process Research and Development, Merck & Company, Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - Birgit Kosjek
- Process Research and Development, Merck & Company, Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - Yonggang Chen
- Process Research and Development, Merck & Company, Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - Jacob M Janey
- Process Research and Development, Merck & Company, Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - Lushi Tan
- Process Research and Development, Merck & Company, Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| |
Collapse
|
5
|
Zhang M, Zou B, Gunaratna MJ, Weerasekara S, Tong Z, Nguyen TDT, Koldas S, Cao WS, Pascual C, Xie XS, Hua DH. SYNTHESIS OF 1,3,4-OXADIAZOLES AS SELECTIVE T-TYPE CALCIUM CHANNEL INHIBITORS. HETEROCYCLES 2019; 101:145-164. [PMID: 32773946 PMCID: PMC7413294 DOI: 10.3987/com-19-s(f)5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Neuropathic pain, epilepsy, insomnia, and tremor disorder may arrive from an increase of intracellular Ca2+ concentration through a dysfunction of T-type Ca2+ channels. Thus, T-type calcium channels could be a target in drug discovery for the treatments of neuropathic pain and epilepsy. From rational drug design approach, a group of 2,5-disubstituted 1,3,4-oxadiazole molecules was synthesized and their selective T-type channel inhibitions were evaluated. The synthetic strategy consists of a short sequence of three reactions: (i) condensation of thiosemicarbazide with acid chlorides; (ii) ring closing by 1,3-dibromo-5,5- dimethylhydantoin; and (iii) coupling with various acid chlorides. 5-Chloro-N-(5- phenyl-1,3,4-oxadiazol-2-yl)thiophene-2-carboxamide (11) was found to selectively inhibit T-type Ca2+ channel over Na+ and K+ channels in mouse dorsal root ganglion neurons and/or human embryonic kidney (HEK)-293 cells and to suppress seizure-induced death in mouse model. Consequently, compound 11 is a useful probe for investigation of physiologic and pathophysiologic roles of the T-channel, and provides a basis to develop a novel therapeutic to treat chronic neuropathic and inflammatory pains.
Collapse
Affiliation(s)
- Man Zhang
- Department of Chemistry, Kansas State University, 1212 Mid Campus Drive, Manhattan, KS 66506, U. S. A
| | - Bende Zou
- AfaSci Research Laboratories, Redwood City, CA 94063, U. S. A
| | - Medha J Gunaratna
- Department of Chemistry, Kansas State University, 1212 Mid Campus Drive, Manhattan, KS 66506, U. S. A
| | - Sahani Weerasekara
- Department of Chemistry, Kansas State University, 1212 Mid Campus Drive, Manhattan, KS 66506, U. S. A
| | - Zongbo Tong
- Department of Chemistry, Kansas State University, 1212 Mid Campus Drive, Manhattan, KS 66506, U. S. A
| | - Thi D T Nguyen
- Department of Chemistry, Kansas State University, 1212 Mid Campus Drive, Manhattan, KS 66506, U. S. A
| | - Serkan Koldas
- Department of Chemistry, Kansas State University, 1212 Mid Campus Drive, Manhattan, KS 66506, U. S. A
| | - William S Cao
- AfaSci Research Laboratories, Redwood City, CA 94063, U. S. A
| | - Conrado Pascual
- AfaSci Research Laboratories, Redwood City, CA 94063, U. S. A
| | | | - Duy H Hua
- Department of Chemistry, Kansas State University, 1212 Mid Campus Drive, Manhattan, KS 66506, U. S. A
| |
Collapse
|
6
|
Sairaman A, Cardoso FC, Bispat A, Lewis RJ, Duggan PJ, Tuck KL. Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels. Bioorg Med Chem 2018; 26:3046-3059. [DOI: 10.1016/j.bmc.2018.03.031] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 03/15/2018] [Accepted: 03/18/2018] [Indexed: 10/17/2022]
|
7
|
Bezençon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, Corminboeuf O, Roch C, Kessler M, Ertel EA, Reymond I, Pfeifer T, de Kanter R, Toeroek-Schafroth M, Moccia LG, Mawet J, Moon R, Rey M, Capeleto B, Fournier E. Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. J Med Chem 2017; 60:9769-9789. [PMID: 29116786 DOI: 10.1021/acs.jmedchem.7b01236] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.
Collapse
Affiliation(s)
- Olivier Bezençon
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Bibia Heidmann
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Romain Siegrist
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Simon Stamm
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Sylvia Richard
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Davide Pozzi
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Olivier Corminboeuf
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Catherine Roch
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Melanie Kessler
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Eric A Ertel
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Isabelle Reymond
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Thomas Pfeifer
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Ruben de Kanter
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Michael Toeroek-Schafroth
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Luca G Moccia
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Jacques Mawet
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Richard Moon
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Markus Rey
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Bruno Capeleto
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Elvire Fournier
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| |
Collapse
|
8
|
Cain SM, Ahn S, Garcia E, Zhang Y, Waheed Z, Tyson JR, Yang Y, Van Sung T, Phillips AG, Snutch TP. Heantos-4, a natural plant extract used in the treatment of drug addiction, modulates T-type calcium channels and thalamocortical burst-firing. Mol Brain 2016; 9:94. [PMID: 27919294 PMCID: PMC5139062 DOI: 10.1186/s13041-016-0274-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Accepted: 11/21/2016] [Indexed: 11/10/2022] Open
Abstract
Heantos-4 is a refined combination of plant extracts currently approved to treat opiate addiction in Vietnam. In addition to its beneficial effects on withdrawal and prevention of relapse, reports of sedation during clinical treatment suggest that arousal networks in the brain may be recruited during Heantos administration. T-type calcium channels are implicated in the generation of sleep rhythms and in this study we examined whether a Heantos-4 extraction modulates T-type calcium channel currents generated by the Cav3.1, Cav3.2 and Ca3.3 subtypes. Utilizing whole-cell voltage clamp on exogenously expressed T-type calcium channels we find that Heantos inhibits Cav3.1 and Cav3.3 currents, while selectively potentiating Cav3.2 currents. We further examined the effects of Heantos-4 extract on low-threshold burst-firing in thalamic neurons which contribute to sleep oscillations. Using whole-cell current clamp in acute thalamic brain slices Heantos-4 suppressed rebound burst-firing in ventrobasal thalamocortical neurons, which express primarily Cav3.1 channels. Conversely, Heantos-4 had no significant effect on the burst-firing properties of thalamic reticular neurons, which express a mixed population of Cav3.2 and Cav3.3 channels. Examining Heantos-4 effects following oral administration in a model of absence epilepsy revealed the potential to exacerbate seizure activity. Together, the findings indicate that Heantos-4 has selective effects both on specific T-type calcium channel isoforms and distinct populations of thalamic neurons providing a putative mechanism underlying its effects on sedation and on the thalamocortical network.
Collapse
Affiliation(s)
- Stuart M Cain
- Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 219-2185 East Mall, Vancouver, BC, V6T 1Z4, Canada
| | - Soyon Ahn
- Department of Psychiatry, University of British Columbia, Vancouver, Canada
| | - Esperanza Garcia
- Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 219-2185 East Mall, Vancouver, BC, V6T 1Z4, Canada
| | - Yiming Zhang
- Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 219-2185 East Mall, Vancouver, BC, V6T 1Z4, Canada
| | - Zeina Waheed
- Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 219-2185 East Mall, Vancouver, BC, V6T 1Z4, Canada
| | - John R Tyson
- Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 219-2185 East Mall, Vancouver, BC, V6T 1Z4, Canada
| | - Yi Yang
- Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 219-2185 East Mall, Vancouver, BC, V6T 1Z4, Canada
| | - Tran Van Sung
- Institute of Chemistry, Vietnam Academy of Science and Technology, Hanoi, Vietnam
| | - Anthony G Phillips
- Department of Psychiatry, University of British Columbia, Vancouver, Canada
| | - Terrance P Snutch
- Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 219-2185 East Mall, Vancouver, BC, V6T 1Z4, Canada. .,Department of Psychiatry, University of British Columbia, Vancouver, Canada.
| |
Collapse
|
9
|
Siegrist R, Pozzi D, Jacob G, Torrisi C, Colas K, Braibant B, Mawet J, Pfeifer T, de Kanter R, Roch C, Kessler M, Corminboeuf O, Bezençon O. Structure–Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers. J Med Chem 2016; 59:10661-10675. [DOI: 10.1021/acs.jmedchem.6b01356] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Romain Siegrist
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Davide Pozzi
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Gaël Jacob
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Caterina Torrisi
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Kilian Colas
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Bertrand Braibant
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Jacques Mawet
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Thomas Pfeifer
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Ruben de Kanter
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Catherine Roch
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Melanie Kessler
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Olivier Corminboeuf
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Olivier Bezençon
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| |
Collapse
|
10
|
Remen L, Bezençon O, Simons L, Gaston R, Downing D, Gatfield J, Roch C, Kessler M, Mosbacher J, Pfeifer T, Grisostomi C, Rey M, Ertel EA, Moon R. Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers. J Med Chem 2016; 59:8398-411. [DOI: 10.1021/acs.jmedchem.6b00756] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Lubos Remen
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Olivier Bezençon
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Lloyd Simons
- Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, Michigan 49008, United States
| | - Rick Gaston
- Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, Michigan 49008, United States
| | - Dennis Downing
- Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, Michigan 49008, United States
| | - John Gatfield
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Catherine Roch
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Melanie Kessler
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Johannes Mosbacher
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Thomas Pfeifer
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Corinna Grisostomi
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Markus Rey
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Eric A. Ertel
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| | - Richard Moon
- Drug
Discovery Chemistry, Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
| |
Collapse
|
11
|
Raymer B, Ebner D. Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014). Expert Opin Ther Pat 2015; 25:1175-90. [PMID: 26173447 DOI: 10.1517/13543776.2015.1061997] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
INTRODUCTION Chronic heart failure (CHF) is the long-term inability of the heart to meet circulatory demands under normal conditions. Effects of CHF can include increased blood volume, increased vascular resistance and compromised contractility leading to fluid retention, dyspnea and fatigue. Current standard of care for chronic systolic heart failure is directed towards managing hypoperfusion through the renin-angiotensin-aldosterone and sympathetic nervous systems. Treatment may also involve reversal of maladaptive cardiac remodeling and prevention of life-threatening arrhythmias. AREAS COVERED This review highlights small molecule and peptidic agents for the treatment of CHF with patents published between 2011 and 2014. Targets are subdivided into inotropic agents, ventricular remodeling, diuretics and the renin-angiotensin-aldosterone system. EXPERT OPINION CHF represents a large, unmet medical need where improved therapies are needed. The renin-angiotensin-aldosterone system pathway continues to be a major source of new therapies for CHF with new inotropic therapies emerging. Promising initial clinical results for a few approaches combined with the expectation of additional clinical results in the near future make this an exciting time in the pursuit of new treatments for CHF.
Collapse
Affiliation(s)
- Brian Raymer
- a Cardiovascular, Metabolic, and Endocrine Diseases Chemistry, Pfizer Worldwide Research and Development , Cambridge, MA, USA +1 617 551 3414 ; +1 617 551 3082 ;
| | - David Ebner
- a Cardiovascular, Metabolic, and Endocrine Diseases Chemistry, Pfizer Worldwide Research and Development , Cambridge, MA, USA +1 617 551 3414 ; +1 617 551 3082 ;
| |
Collapse
|
12
|
Zhang Q, Xia Z, Joshi S, Scott VE, Jarvis MF. Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639. ACS Med Chem Lett 2015; 6:641-4. [PMID: 26101566 DOI: 10.1021/acsmedchemlett.5b00023] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2015] [Accepted: 04/28/2015] [Indexed: 11/30/2022] Open
Abstract
The discovery of a novel peripherally acting and selective Cav3.2 T-type calcium channel blocker, ABT-639, is described. HTS hits 1 and 2, which have poor metabolic stability, were optimized to obtain 4, which has improved stability and oral bioavailability. Modification of 4 to further improve ADME properties led to the discovery of ABT-639. Following oral administration, ABT-639 produces robust antinociceptive activity in experimental pain models at doses that do not significantly alter psychomotor or hemodynamic function in the rat.
Collapse
Affiliation(s)
- Qingwei Zhang
- Neuroscience
Research, AbbVie, 1 North Waukegan Road, North
Chicago, Illinois 60064, United States
| | - Zhiren Xia
- Neuroscience
Research, AbbVie, 1 North Waukegan Road, North
Chicago, Illinois 60064, United States
| | - Shailen Joshi
- Neuroscience
Research, AbbVie, 1 North Waukegan Road, North
Chicago, Illinois 60064, United States
| | - Victoria E. Scott
- Neuroscience
Research, AbbVie, 1 North Waukegan Road, North
Chicago, Illinois 60064, United States
| | - Michael F. Jarvis
- Neuroscience
Research, AbbVie, 1 North Waukegan Road, North
Chicago, Illinois 60064, United States
| |
Collapse
|
13
|
Zhou FJ, Nian Y, Yan Y, Gong Y, Luo Q, Zhang Y, Hou B, Zuo ZL, Wang SM, Jiang HH, Yang J, Cheng YX. Two New Classes of T-Type Calcium Channel Inhibitors with New Chemical Scaffolds from Ganoderma cochlear. Org Lett 2015; 17:3082-5. [PMID: 26024438 DOI: 10.1021/acs.orglett.5b01353] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Feng-Jiao Zhou
- State
Key Laboratory of Phytochemistry and Plant Resources in West China,
Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, P.R. China
- Guangdong Pharmaceutical University, Guangzhou 510006, P.R. China
| | - Yin Nian
- Key
Laboratory of Animal Models and Human Disease Mechanisms, and Ion
Channel Research and Drug Development Center, Kunming Institute of
Zoology, Chinese Academy of Sciences, Kunming 650223, P.R. China
| | - Yongming Yan
- State
Key Laboratory of Phytochemistry and Plant Resources in West China,
Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, P.R. China
- University of Chinese Academy of Sciences, Beijing 100049, P.R. China
| | - Ye Gong
- Key
Laboratory of Animal Models and Human Disease Mechanisms, and Ion
Channel Research and Drug Development Center, Kunming Institute of
Zoology, Chinese Academy of Sciences, Kunming 650223, P.R. China
| | - Qi Luo
- State
Key Laboratory of Phytochemistry and Plant Resources in West China,
Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, P.R. China
- University of Chinese Academy of Sciences, Beijing 100049, P.R. China
| | - Yu Zhang
- State
Key Laboratory of Phytochemistry and Plant Resources in West China,
Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, P.R. China
| | - Bo Hou
- State
Key Laboratory of Phytochemistry and Plant Resources in West China,
Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, P.R. China
| | - Zhi-Li Zuo
- State
Key Laboratory of Phytochemistry and Plant Resources in West China,
Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, P.R. China
| | - Shu-Mei Wang
- Guangdong Pharmaceutical University, Guangzhou 510006, P.R. China
| | - He-Hai Jiang
- Key
Laboratory of Animal Models and Human Disease Mechanisms, and Ion
Channel Research and Drug Development Center, Kunming Institute of
Zoology, Chinese Academy of Sciences, Kunming 650223, P.R. China
| | - Jian Yang
- Key
Laboratory of Animal Models and Human Disease Mechanisms, and Ion
Channel Research and Drug Development Center, Kunming Institute of
Zoology, Chinese Academy of Sciences, Kunming 650223, P.R. China
- Department
of Biological Sciences, Columbia University, New York, New York 10027, United States
| | - Yong-Xian Cheng
- State
Key Laboratory of Phytochemistry and Plant Resources in West China,
Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, P.R. China
| |
Collapse
|
14
|
Reger TS, Yang ZQ, Schlegel KAS, Shu Y, Mattern C, Cube R, Rittle KE, McGaughey GB, Hartman GD, Tang C, Ballard J, Kuo Y, Prueksaritanont T, Nuss CE, Doran SM, Fox SV, Garson SL, Li Y, Kraus RL, Uebele VN, Renger JJ, Barrow JC. Pyridyl amides as potent inhibitors of T-type calcium channels. Bioorg Med Chem Lett 2011; 21:1692-6. [PMID: 21316226 DOI: 10.1016/j.bmcl.2011.01.089] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2010] [Revised: 01/19/2011] [Accepted: 01/20/2011] [Indexed: 11/18/2022]
Abstract
A novel series of amide T-type calcium channel antagonists were prepared and evaluated using in vitro and in vivo assays. Optimization of the screening hit 3 led to identification of the potent and selective T-type antagonist 37 that displayed in vivo efficacy in rodent models of epilepsy and sleep.
Collapse
Affiliation(s)
- Thomas S Reger
- Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|